Treating hypertension is complex, and European guidelines reinforce the safety and effectiveness of renal denervation as a treatment option to improve hypertension control
Palo Alto, Calif. – July 14, 2023 – ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) presented at their 32nd annual European Meeting on Hypertension and Cardiovascular Protection. The new guidelines are designed to serve as a resource on the latest scientific evidence for healthcare professionals around the world who treat people with hypertension. Current rates of treatment and control of hypertension remain suboptimal, and the ESH guidelines assist clinicians and patients in achieving the goal of better health.
The 2023 ESH Guidelines for the Management of Arterial Hypertension, endorsed by the European Renal Association (ERA) and the International Society of Hypertension, were officially presented at ESH and simultaneously published in the Journal of Hypertension[1]. The guidelines include recommendations for the use of renal denervation, which can be considered, 1) as an additional treatment option for patients with resistant hypertension on three or more antihypertensive medications, 2) as a treatment option for patients with uncontrolled hypertension despite the use of antihypertensive drug combination therapy, or 3) if a patient’s drug treatment elicits serious side effects and poor quality of life.
“Recommendation of renal denervation by the recently published European Society of Hypertension (ESH) 2023 Guidelines is a significant milestone for the field of arterial hypertension management. The decision to consider renal denervation as a treatment option is based on the demonstrated efficacy and safety of the procedure in the published results of several rigorous randomized and sham-controlled trials,” said Michel Azizi, Professor of Medicine at Université Paris Cité, Hôpital Européen Georges Pompidou, Paris, France. “The recommendations state that renal denervation should be performed in experienced specialized centers, and that the process of patient selection should be done by a multidisciplinary team.”
__________________
[1] Mancia Chairperson G, Kreutz Co-Chair R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank K, Cunha PG, Danser AHJ, de Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE; Authors/Task Force Members:. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023 Jun 21. doi: 10.1097/HJH.0000000000003480. Epub ahead of print. PMID: 37345492.
ReCor Medical has completed three global, independently powered, sham-controlled randomized clinical trials of the Paradise™ Ultrasound Renal Denervation (RDN) System in more than 500 patients with uncontrolled hypertension. The RADIANCE-HTN SOLO, RADIANCE-HTN TRIO and RADIANCE II clinical studies met their prespecified primary efficacy endpoints of blood pressure reduction, with positive safety outcomes.
“The ESH guidelines support the experience of European clinicians who are already using the Paradise Ultrasound RDN System for some patients who need an additional treatment option to achieve meaningful reductions in blood pressure,” said ReCor President and CEO, Lara Barghout. “The urgent global need to address the burden of uncontrolled hypertension remains, and we’re committed to revolutionizing the way hypertension is treated and bringing the benefits of ultrasound RDN to patients who need it. In the coming months, we will work with the FDA to complete their review of our PMA seeking approval of ultrasound RDN in the U.S.”
In November 2022, ReCor Medical announced its submission of a pre-market approval application for the Paradise Ultrasound RDN System to the U.S. Food and Drug Administration (FDA). The FDA Circulatory Systems Devices Panel of the Medical Devices Advisory Committee will hold a meeting virtually on Aug. 22-23, 2023, to discuss, make recommendations and vote on devices indicated to reduce blood pressure in patients with hypertension.
The Paradise Ultrasound RDN System bears the CE mark for the treatment of hypertension in Europe and is an investigational device in the United States and Japan.
About ReCor Medical, Inc.
ReCor Medical, headquartered in Palo Alto, CA, a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. ReCor has pioneered the use of the Paradise Ultrasound Renal Denervation (uRDN) System for the treatment of hypertension. The Paradise System is an investigational device in the United States and Japan and bears the CE mark in the EU. ReCor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise System in patients with mild-to-moderate and resistant hypertension, and has submitted an application for PMA approval in the United States with the U.S. FDA. In addition, ReCor has begun the Global Paradise System (“GPS”) Registry in the European Union, with plans to expand globally.
About Otsuka Medical Devices Co., Ltd.
Otsuka Medical Devices focuses on the global development and commercialization of medical care products including endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices Co., Ltd. is a subsidiary of Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578).
https://www.omd.otsuka.com/en/
Media Contact
Annika Parrish
Health+Commerce
annika@healthandcommerce.com
